HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial


TRATAMENTO NEOADJUVANTE COM TDM1+ PERTUZUMAB FOI MUITO BEM ACEITO POR 95% DOS PACIENTES COM PCR : 55% , LEVANDO EM CONTA HETEROGENIDADE TUMORAL DO HER -2 , ESTAR INDEPENDENTE DO RECEPTOR DE ESTROGÊNIO , A HETEROGENIEDADE INTRATUMORAL PODE ESTAR ASSOCIADO A BAIXA TAXA DE RESPOSTA PATOLÓGICA , BAIXO NÍVEL DE EXPRESSÃO PROTEÍNA HER2 


















Comentários

Postar um comentário

Postagens mais visitadas deste blog

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis

http://www.nature.com/articles/srep06269 Abstract Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR mutation in tissues has obvious limitations. Circulating free DNA (cfDNA) has been reported as an alternative approach for the detection of EGFR mutations. This systematic review and meta-analysis was designed to assess the diagnostic performance of cfDNA, compared with tissues. True-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) values were extracted or calculated for each study. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated. A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall diagnostic performance. 20 eligible studies involving 2012 cases were included in this m...
Leia mais